• Skip to main content

DistilGovHealth

DistilNFO GovHealth Advisory

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Generic Drugs ‘Wildly Overpriced’ in Medicare, Study Finds

Share:

July 23, 2019

Many generic drugs in Medicare Part D are “wildly overpriced,” according to an analysis from drug pricing research firm 46brooklyn.

The report, which examined data from CMS’ Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files, found that while some generic drugs are priced fairly, others “show unbelievable pricing variations across Part D plans.”

Three things to know:

1. Researchers found in the first quarter of 2019, for example, that Medicare Part D sponsors priced generic mental disorder drug aripiprazole — brand name Abilify — anywhere from less than $0.30 per pill to more than $22 per pill.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

2. In addition to being overpriced, many generic drugs are “over-tiered,” the researchers found. This means generic drugs that are usually less expensive are being assigned higher, often arbitrary prices. They are then placed in tiers used for more expensive drugs. This results in beneficiaries paying more out of pocket to access the drugs.

3. According to the analysis, pricing did not vary much among brand-name drugs, which was not surprising to the researchers. Still, some of the charts they created show “cliffs” that may indicate plans are pricing brand drugs lower than list price.

Date: 24 July, 2019

Source : Beckers Hospital Review

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Building Data Culture a Priority as AI Investments Ramp UpBuilding Data Culture a Priority as AI Investments Ramp Up
  • RTI – Delivering the Promise of Science for Global GoodRTI – Delivering the Promise of Science for Global Good
  • In-app Chat: The Future of Secure Doctor/Patient Communications?In-app Chat: The Future of Secure Doctor/Patient Communications?
  • Conservative Groups Aim to Sink Bipartisan Fix to ’Surprise’ Medical BillsConservative Groups Aim to Sink Bipartisan Fix to ’Surprise’ Medical Bills
  • Envisioning a Better U.S. Health Care System for All: A Call to Action By the American College of PhysiciansEnvisioning a Better U.S. Health Care System for All: A Call to Action By the American College of Physicians
  • Physicians dissatisfied with bundled payments, value-based care and more: 3 report findingsPhysicians dissatisfied with bundled payments, value-based care and more: 3 report findings

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications